Inmed joins Logex
Root/Amsterdam - The Lucerne-based company Inmed is being taken over by Logex. The two companies are specialists in data-based Software-as-a-Service solutions and analytics for the healthcare sector. Together, the aim will be to enhance the quality and depth of their approaches.
Headquartered at Technopark Luzern in Root in the canton of Lucerne, Switzerland, Inmed is set to join the Amsterdam-based firm Logex, which is known as the European market leader in the field of health data analytics. Inmed operates in the same segment, specializing in the optimization of clinical management across the German-speaking DACH (Germany, Austria and Switzerland) region. As detailed in a press release, the companies will jointly deliver «even more advanced data analytics and valuable insights to enhance European healthcare systems».
According to the press release, it is important that hospital decisions lead to the best possible outcomes in the face of increasingly scarce resources. For this reason, Logex and Inmed offer data-based Software-as-a-Service solutions and analytics to decision-makers in the healthcare sector. Logex primarily offers its services to hospitals in areas such as financial analytics, operating room performance evaluations, patient engagement and real-world data. With its SMARTlize! platform, Inmed is keen to play its part in improving clinical performance through medical controlling, strategic hospital planning and market position analyses.
In the words of Logex’s CEO Philipp Jan Flach, his company is excited about the opportunity to «further enhance the quality and depth of our analytics and extend our services to even more healthcare providers across Europe» following the combination of the two firms.
Both of the founders of Inmed will also be making the switch to Logex. In partnership with Logex, Inmed can «now offer an even more complete strategic picture to hospital management», as Jörg Zirklewski, one of the two co-founders, states in the press release. «This helps us make a real impact that matters to millions of patients. We are excited about this combined journey», he concludes.
